MASH

reading MASH threads from 2024 and half of it aged badly. It is the sort of thing everyone half-believes and nobody writes down. Histological endpoints in this field…

Check-in as promised in the title: is it normal to get muscle cramps at week 88. Nothing containing this compound is approved anywhere. Research-use-only material is…

28 weeks on 10mg, full numbers, ask me anything boring. This is a description of what happened to me and not a plan for anybody else. Numbers, in the order they matter:…

small win: glucagon stopped being a problem at week 36. This is a description of what happened to me and not a plan for anybody else. The endpoint vocabulary, because…

4 months in and hepatic fat is still the thing I get wrong, logged the same way every week so the comparison is at least internally fair. The numbers the title…

why does nobody talk about MASH, and I want the answer with the reasoning attached rather than just the conclusion. What this compound is actually being developed for,…

Something I keep coming back to: my ALT moved and I cannot work out whether dual agonist is why. Imaging-derived liver fat fraction is a surrogate. It correlates with…

Something I keep coming back to: glucagon is the most under-discussed thing on this board. Imaging-derived liver fat fraction is a surrogate. It correlates with…

Homopeptide survo — Medutest came back 98.4% against a claimed 98.0%. One vial, one service, one member paying, which is the only kind of result this board should treat…

Asking properly rather than in a comment on somebody else’s thread: how do you actually verify biopsy. Went slowly because everything published describes a deliberate…

anyone else notice glucagon kicking in around week 47. Full detail below, and I have tried to keep the editorialising out of it. Imaging-derived liver fat fraction is a…

the MASH thing finally clicked for me and I want to write it down, which sounds obvious until you try to state the evidence for it. Independent purity results for this…

how do you actually verify MASH. I would rather ask a basic question now than get this wrong quietly for two months. Read the phase 2 hepatic paper properly and the…

Slightly embarrassed to be asking this, but: genuine question about dual agonist that I am slightly embarrassed to ask. Imaging-derived liver fat fraction is a…

small win: MASH stopped being a problem at week 43. Full detail below, and I have tried to keep the editorialising out of it. Imaging-derived liver fat fraction is a…

dual agonist — 21 things I got wrong before I got it right, and I am aware this is a minority view on this board. What this compound is actually being developed for,…

Posting this as a discussion rather than a claim: hepatic fat — 19 things I got wrong before I got it right. Went slowly because everything published describes a…

what changed for me between month 5 and month 8. I am not trying to be the "source?" guy. I would just like a source. Assumed the weight numbers were the point and was…

genuine question about MASH that I am slightly embarrassed to ask. I would rather ask a basic question now than get this wrong quietly for two months. Asked here what…

Short version of the title, which is already short: 24th independent test on QSC — 98.4% on a claimed 98.0%, and the trend is the interesting part. Longer version…

biopsy is the most under-discussed thing on this board. I have gone back and forth on this for months. Phase 2 in a biopsy-confirmed population is a demanding design:…

three years of survodutide threads, summarised so you do not have to read them. Not a hot take, just something I have not seen said plainly here. Histological endpoints…

Slightly embarrassed to be asking this, but: why does nobody talk about biopsy. Bought small because the evidence base is early. That is the only defensible position I…

Thinking out loud about this: phase 2 biopsy endpoints, and what "resolution" means. The honest evidence position, written out so this board does not drift. Phase 2…

stalled for 8 weeks at 1.7mg and I refuse to panic this time. Making the case below, and I expect to lose some of it in the comments. Since the title puts numbers in…